Literature DB >> 8492953

Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease.

R L Doty1, L I Golbe, D A McKeown, M B Stern, C M Lehrach, D Crawford.   

Abstract

Olfactory dysfunction occurs in most patients with idiopathic Parkinson's disease (PD). In this study, we sought to determine whether such dysfunction is also present in progressive supranuclear palsy (PSP), a condition which shares a number of motor symptoms with PD and is commonly misdiagnosed as PD. We administered the University of Pennsylvania Smell Identification Test, a standardized test of odor identification ability, to 21 PSP patients; 17 also received a forced-choice odor detection threshold test. We compared the olfactory test scores to those obtained from PD patients and normal controls matched to the PSP patients on the basis of age, sex, and smoking habits. Overall, the olfactory function of the PSP patients was markedly superior to that of the PD patients and did not differ significantly from that of the normal controls. There was no association in either the PSP or PD patient groups between (1) the olfactory test scores and (2) measures of motor symptom severity, disease stage, and medication usage. These findings demonstrate that patients with PSP and PD differ markedly in their ability to smell and suggest that olfactory testing may be useful in their differential diagnosis.

Entities:  

Mesh:

Year:  1993        PMID: 8492953     DOI: 10.1212/wnl.43.5.962

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

1.  Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease.

Authors:  Steven E Arnold; Edward B Lee; Paul J Moberg; Lauren Stutzbach; Hala Kazi; Li-Ying Han; Virginia M Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

Review 2.  Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Filipe C Matheus; Roger Walz; Layal Antoury; Rita Raisman-Vozari; Richard L Doty
Journal:  Neurotox Res       Date:  2011-10-15       Impact factor: 3.911

3.  Olfactory dysfunction in LRRK2 G2019S mutation carriers.

Authors:  R Saunders-Pullman; K Stanley; C Wang; M San Luciano; V Shanker; A Hunt; L Severt; D Raymond; L J Ozelius; R B Lipton; S B Bressman
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

Review 4.  Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease.

Authors:  Michelle E Fullard; James F Morley; John E Duda
Journal:  Neurosci Bull       Date:  2017-08-22       Impact factor: 5.203

Review 5.  Preclinical diagnosis of Parkinson's disease: are we there yet?

Authors:  Andrew Siderowf; Matthew B Stern
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

6.  Olfactory dysfunction in the Shy-Drager syndrome.

Authors:  L E Nee; J Scott; R J Polinsky
Journal:  Clin Auton Res       Date:  1993-08       Impact factor: 4.435

Review 7.  Anorexia in older persons: epidemiology and optimal treatment.

Authors:  J E Morley
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 8.  Olfactory loss as a supporting feature in the diagnosis of Parkinson's disease: a pragmatic approach.

Authors:  Katie Hoyles; Jagdish C Sharma
Journal:  J Neurol       Date:  2013-02-03       Impact factor: 4.849

9.  The lateralized smell test for detecting Alzheimer's disease: failure to replicate.

Authors:  Richard L Doty; Edgardo A Bayona; Daniel S Leon-Ariza; Juan Cuadros; Inna Chung; Britney Vazquez; Fidias E Leon-Sarmiento
Journal:  J Neurol Sci       Date:  2014-03-19       Impact factor: 3.181

10.  Prodromal non-motor symptoms of Parkinson's disease.

Authors:  Clelia Pellicano; Dario Benincasa; Vincenzo Pisani; Francesca R Buttarelli; Morena Giovannelli; Francesco E Pontieri
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.